NanoLive

NanoLive has pioneered an integrated platform for label-free, high-content live cell imaging and analysis, targeting the drug discovery and diagnostics sectors. Its flagship 3D Cell Explorer systems utilize a patented holotomography technology to generate quantitative, phototoxicity-free data, which is then analyzed by a suite of AI-driven digital assays for specific applications like cytotoxicity, immuno-oncology, and mitochondrial analysis. The company operates as a private, commercial-stage entity, selling its instruments and software as a platform to academic, biopharma, and industrial research customers, enabling them to accelerate and de-risk early-stage research and screening workflows.

Holotomography (HT) - a label-free, non-invasive 3D live-cell imaging technology combining holography (quantitative phase imaging) and tomography (multi-angle reconstruction), paired with AI-powered digital assays for automated analysis of specific cellular phenotypes.

NanoLive competes in the high-content screening and live-cell imaging market against large players like PerkinElmer, Thermo Fisher Scientific, and Yokogawa, who primarily offer label-based systems. It also faces competition from other label-free techniques such as impedance-based systems (e.g., ACEA/Agilent xCELLigence) and other quantitative phase imaging methods. Its differentiation lies in the combination of high-resolution 3D holotomography, long-term viability, and application-specific AI analysis.